P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 C...

por Spira, A., Liao, L., Zhou, X., Gnanasakthy, A., Chen, L., Ungar, D., Yu, E., Kilavuz, T., Radford, J., Hamadani, M.
Publicado 2022

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

por Hamadani, M., Graham, C. N., Liao, L., Zhang, K. H., Strat, H., Ungar, D., Ai, W., Chen, L., Carlo-Stella, C.
Publicado 2022

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)

por Hamadani, M., Linhares, Y., Gandhi, M. D., Chung, M., Adamis, H., Ungar, D., Carlo-Stella, C., Kingsley, E., Depaus, J., Snauwaert, S., Kwiatek, M., López-Jiménez, J.
Publicado 2022